Navigation Links
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Date:11/21/2007

out ACTEMRA

The clinical development program conducted by Roche includes five clinical studies and has enrolled more than 4,000 patients in 40 countries, including the U.S. One of these Phase III trials evaluating ACTEMRA in RA is an ongoing two-year study and is expected to report one-year data evaluating the effect of ACTEMRA on the inhibition of structural damage in 2008.

ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. ACTEMRA was launched in Japan by Chugai in June 2005 as a therapy for Castleman's disease. Additional indications for RA and systemic-onset juvenile idiopathic arthritis were also filed in Japan in April 2006 and are currently under review.

The serious adverse events reported in ACTEMRA clinical trials were serious infections and hypersensitivity reactions including anaphylaxis. The most common adverse events reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. Increases in liver function tests (ALT and AST) were seen in some patients; these increases were generally mild and reversible, with no hepatic injuries or any observed impact on liver function.

About Rheumatoid Arthritis

Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. Characteristics of RA include redness, swelling, pain and movement limitation around joints of the hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin and osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50% of patients can continue to work or function normally on a daily basis. RA a
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
10. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
11. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... YORK , March 30, 2015  Check-Cap Ltd. ... company focused on the development of a preparation-free ingestible ... for colorectal cancer, announced today that its CEO, Guy ... March 31, 2015 trading day.  Neev and Check-Cap will ... commemorate the company,s initial public offering and simultaneous private ...
(Date:3/30/2015)... Perrigo Company plc (NYSE: PRGO ; TASE), a ... announced that it has completed the acquisition of Belgian-based ... equity transaction valued at approximately €3.8 billion, which includes ... Marc Coucke , Waterland Private Equity Fund V ... "The combination of Perrigo and Omega creates an ...
(Date:3/30/2015)... 2015  MedAptus® today announced the launch of ... pre-care needs for busy inpatient provider teams. Assign ... patients to hospitalists or other rounding providers based ... requirements such as ensuring patient safety, proper reimbursement ... In an increasingly risk-based ...
Breaking Medicine Technology:Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 2Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 4Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 5MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 2MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 3
(Date:3/30/2015)... Follow us on LinkedIn ... and establish chronic pain rehabilitation centers are driving demand ... is poised to benefit from the rise in acute ... in chronic health conditions such as Cancer, degenerative diseases, ... While conventional treatment for pain management is dominated by ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 On March ... Ford Field, home of the Detroit Lions, LiveToBeSober.org hosted ... nationally recognized pastors, ministers and bishops as well as ... addressed the audience at the luncheon, including retired Detroit ... sponsor Per Wickstrom and two survivors of their own ...
(Date:3/30/2015)... Dr. Daniel Shapiro, one of the t ... on Phoenix’s Channel 12 News about the benefits of his ... alternative to facelifts developed by Dr. Shapiro. , Over the ... Aesthetic Plastic Surgery and Skin Klinic worked closely with 12 ... on GenXLift. The story detailed the experience and results of ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 On ... blue polo for yellow to inspire courage in Seth ... from Severe Combined Immunodeficiency (SCID). SCID causes affected individuals ... marrow transplant is needed to allow the development of ... transplant last Friday, created a video with his family ...
(Date:3/30/2015)... 2015 DMG Productions announces the upcoming ... broadcast on Monday, April 20, 2015 at 7:30 a.m. ... , In this episode Innovations will explore Limbkeepers® non ... fragile, thinning skin on arms, hands, and legs from ... on how their products help reduce injuries, allow for ...
Breaking Medicine News(10 mins):Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:Dr. Daniel Shapiro Unveils New Minimally Invasive Facelift Procedure on Local Newscast 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:New Episode of Innovations Airing Monday, April 20, 2015 Via Discovery Channel 2
... (HealthDay News) -- Personal independence and freedom are more important ... Researchers at the Victoria University of Wellington in New Zealand ... of more than 420,000 people from 63 countries and spanned ... autonomy, but it does not add to well-being or happiness." ...
... Where you get your news could play a significant ... strategy for addressing childhood obesity. According to a study ... of Public Health, whether you believe the keys to ... behavior changes or system-level factors such as marketing and ...
... from the United Kingdom cured well-established prostate tumors in ... effects. This novel cancer treatment approach encourages the immune ... from toxic chemotherapies and radiation treatments. Such a treatment ... free with fewer side effects than those experienced from ...
... -- Whether they are riding with an adult or just ... a running lawn mower, a doctor warns. "Kids should ... the age of 16 should not be allowed to operate ... Harris, pediatric podiatrist with the Loyola University Health System, said ...
... , FRIDAY, June 17 (HealthDay News) -- Last year, ... all U.S. counties, a new study shows. This trend, ... moving away, as well as decreases in fertility levels. Researchers ... (UNH) also found that rural areas are particularly hard hit ...
... LOUISVILLE, Ky. The first three patients to undergo ... involves the patient,s own stem cells continue to do ... the principal investigator. The "TGI-PVG IDE" clinical trial ... cells to line man-made bypass grafts to better the ...
Cached Medicine News:Health News:Freedom More Important to Happiness Than Wealth, Study Finds 2Health News:News source may steer perceived solution to childhood obesity 2Health News:News source may steer perceived solution to childhood obesity 3Health News:Mayo Clinic researchers use human vaccine to cure prostate cancer in mice 2Health News:Adults Reminded to Keep Kids Away From Lawn Mowers 2Health News:Deaths Exceed Births in 24% of U.S. Communities: Report 2Health News:University of Louisville surgeons perform first prosthetic bypass graft with patient's stem cells at point-of-care 2Health News:University of Louisville surgeons perform first prosthetic bypass graft with patient's stem cells at point-of-care 3Health News:University of Louisville surgeons perform first prosthetic bypass graft with patient's stem cells at point-of-care 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: